Accelarated immune ageing is associated with COVID-19 disease severity
© 2024. The Author(s)..
BACKGROUND: The striking increase in COVID-19 severity in older adults provides a clear example of immunesenescence, the age-related remodelling of the immune system. To better characterise the association between convalescent immunesenescence and acute disease severity, we determined the immune phenotype of COVID-19 survivors and non-infected controls.
RESULTS: We performed detailed immune phenotyping of peripheral blood mononuclear cells isolated from 103 COVID-19 survivors 3-5 months post recovery who were classified as having had severe (n = 56; age 53.12 ± 11.30 years), moderate (n = 32; age 52.28 ± 11.43 years) or mild (n = 15; age 49.67 ± 7.30 years) disease and compared with age and sex-matched healthy adults (n = 59; age 50.49 ± 10.68 years). We assessed a broad range of immune cell phenotypes to generate a composite score, IMM-AGE, to determine the degree of immune senescence. We found increased immunesenescence features in severe COVID-19 survivors compared to controls including: a reduced frequency and number of naïve CD4 and CD8 T cells (p < 0.0001); increased frequency of EMRA CD4 (p < 0.003) and CD8 T cells (p < 0.001); a higher frequency (p < 0.0001) and absolute numbers (p < 0.001) of CD28-ve CD57+ve senescent CD4 and CD8 T cells; higher frequency (p < 0.003) and absolute numbers (p < 0.02) of PD-1 expressing exhausted CD8 T cells; a two-fold increase in Th17 polarisation (p < 0.0001); higher frequency of memory B cells (p < 0.001) and increased frequency (p < 0.0001) and numbers (p < 0.001) of CD57+ve senescent NK cells. As a result, the IMM-AGE score was significantly higher in severe COVID-19 survivors than in controls (p < 0.001). Few differences were seen for those with moderate disease and none for mild disease. Regression analysis revealed the only pre-existing variable influencing the IMM-AGE score was South Asian ethnicity ([Formula: see text] = 0.174, p = 0.043), with a major influence being disease severity ([Formula: see text] = 0.188, p = 0.01).
CONCLUSIONS: Our analyses reveal a state of enhanced immune ageing in survivors of severe COVID-19 and suggest this could be related to SARS-Cov-2 infection. Our data support the rationale for trials of anti-immune ageing interventions for improving clinical outcomes in these patients with severe disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Immunity & ageing : I & A - 21(2024), 1 vom: 11. Jan., Seite 6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lord, Janet M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s12979-023-00406-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367033593 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367033593 | ||
| 003 | DE-627 | ||
| 005 | 20240320233933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12979-023-00406-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM367033593 | ||
| 035 | |a (NLM)38212801 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lord, Janet M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Accelarated immune ageing is associated with COVID-19 disease severity |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: The striking increase in COVID-19 severity in older adults provides a clear example of immunesenescence, the age-related remodelling of the immune system. To better characterise the association between convalescent immunesenescence and acute disease severity, we determined the immune phenotype of COVID-19 survivors and non-infected controls | ||
| 520 | |a RESULTS: We performed detailed immune phenotyping of peripheral blood mononuclear cells isolated from 103 COVID-19 survivors 3-5 months post recovery who were classified as having had severe (n = 56; age 53.12 ± 11.30 years), moderate (n = 32; age 52.28 ± 11.43 years) or mild (n = 15; age 49.67 ± 7.30 years) disease and compared with age and sex-matched healthy adults (n = 59; age 50.49 ± 10.68 years). We assessed a broad range of immune cell phenotypes to generate a composite score, IMM-AGE, to determine the degree of immune senescence. We found increased immunesenescence features in severe COVID-19 survivors compared to controls including: a reduced frequency and number of naïve CD4 and CD8 T cells (p < 0.0001); increased frequency of EMRA CD4 (p < 0.003) and CD8 T cells (p < 0.001); a higher frequency (p < 0.0001) and absolute numbers (p < 0.001) of CD28-ve CD57+ve senescent CD4 and CD8 T cells; higher frequency (p < 0.003) and absolute numbers (p < 0.02) of PD-1 expressing exhausted CD8 T cells; a two-fold increase in Th17 polarisation (p < 0.0001); higher frequency of memory B cells (p < 0.001) and increased frequency (p < 0.0001) and numbers (p < 0.001) of CD57+ve senescent NK cells. As a result, the IMM-AGE score was significantly higher in severe COVID-19 survivors than in controls (p < 0.001). Few differences were seen for those with moderate disease and none for mild disease. Regression analysis revealed the only pre-existing variable influencing the IMM-AGE score was South Asian ethnicity ([Formula: see text] = 0.174, p = 0.043), with a major influence being disease severity ([Formula: see text] = 0.188, p = 0.01) | ||
| 520 | |a CONCLUSIONS: Our analyses reveal a state of enhanced immune ageing in survivors of severe COVID-19 and suggest this could be related to SARS-Cov-2 infection. Our data support the rationale for trials of anti-immune ageing interventions for improving clinical outcomes in these patients with severe disease | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Veenith, Tonny |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma-Oates, Archana |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Alex G |e verfasserin |4 aut | |
| 700 | 1 | |a Greening, Neil J |e verfasserin |4 aut | |
| 700 | 1 | |a McAuley, Hamish J C |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Rachael A |e verfasserin |4 aut | |
| 700 | 1 | |a Moss, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Shona C |e verfasserin |4 aut | |
| 700 | 1 | |a Turtle, Lance |e verfasserin |4 aut | |
| 700 | 1 | |a Gautam, Nandan |e verfasserin |4 aut | |
| 700 | 1 | |a Gilani, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Bajaj, Manan |e verfasserin |4 aut | |
| 700 | 1 | |a Wain, Louise V |e verfasserin |4 aut | |
| 700 | 1 | |a Brightling, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Raman, Betty |e verfasserin |4 aut | |
| 700 | 1 | |a Marks, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Singapuri, Amisha |e verfasserin |4 aut | |
| 700 | 1 | |a Elneima, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Openshaw, Peter J M |e verfasserin |4 aut | |
| 700 | 1 | |a Duggal, Niharika A |e verfasserin |4 aut | |
| 700 | 0 | |a PHOSP-COVID Study collaborative group |e verfasserin |4 aut | |
| 700 | 0 | |a ISARIC4C investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Abel, K |e investigator |4 oth | |
| 700 | 1 | |a Adamali, H |e investigator |4 oth | |
| 700 | 1 | |a Adeloye, D |e investigator |4 oth | |
| 700 | 1 | |a Adeyemi, O |e investigator |4 oth | |
| 700 | 1 | |a Adrego, R |e investigator |4 oth | |
| 700 | 1 | |a AguilarJimenez, L A |e investigator |4 oth | |
| 700 | 1 | |a Ahmad, S |e investigator |4 oth | |
| 700 | 1 | |a Ahmad Haider, N |e investigator |4 oth | |
| 700 | 1 | |a Ahmed, R |e investigator |4 oth | |
| 700 | 1 | |a Ahwireng, N |e investigator |4 oth | |
| 700 | 1 | |a Ainsworth, M |e investigator |4 oth | |
| 700 | 1 | |a Al-Sheklly, B |e investigator |4 oth | |
| 700 | 1 | |a Alamoudi, A |e investigator |4 oth | |
| 700 | 1 | |a Ali, M |e investigator |4 oth | |
| 700 | 1 | |a Aljaroof, M |e investigator |4 oth | |
| 700 | 1 | |a All, A M |e investigator |4 oth | |
| 700 | 1 | |a Allan, L |e investigator |4 oth | |
| 700 | 1 | |a Allen, R J |e investigator |4 oth | |
| 700 | 1 | |a Allerton, L |e investigator |4 oth | |
| 700 | 1 | |a Allsop, L |e investigator |4 oth | |
| 700 | 1 | |a Almeida, P |e investigator |4 oth | |
| 700 | 1 | |a Altmann, D |e investigator |4 oth | |
| 700 | 1 | |a Alvarez Corral, M |e investigator |4 oth | |
| 700 | 1 | |a Amoils, S |e investigator |4 oth | |
| 700 | 1 | |a Anderson, D |e investigator |4 oth | |
| 700 | 1 | |a Antoniades, C |e investigator |4 oth | |
| 700 | 1 | |a Arbane, G |e investigator |4 oth | |
| 700 | 1 | |a Arias, A |e investigator |4 oth | |
| 700 | 1 | |a Armour, C |e investigator |4 oth | |
| 700 | 1 | |a Armstrong, L |e investigator |4 oth | |
| 700 | 1 | |a Armstrong, N |e investigator |4 oth | |
| 700 | 1 | |a Arnold, D |e investigator |4 oth | |
| 700 | 1 | |a Arnold, H |e investigator |4 oth | |
| 700 | 1 | |a Ashish, A |e investigator |4 oth | |
| 700 | 1 | |a Ashworth, A |e investigator |4 oth | |
| 700 | 1 | |a Ashworth, M |e investigator |4 oth | |
| 700 | 1 | |a Aslani, S |e investigator |4 oth | |
| 700 | 1 | |a Assefa-Kebede, H |e investigator |4 oth | |
| 700 | 1 | |a Atkin, C |e investigator |4 oth | |
| 700 | 1 | |a Atkin, P |e investigator |4 oth | |
| 700 | 1 | |a Aul, R |e investigator |4 oth | |
| 700 | 1 | |a Aung, H |e investigator |4 oth | |
| 700 | 1 | |a Austin, L |e investigator |4 oth | |
| 700 | 1 | |a Avram, C |e investigator |4 oth | |
| 700 | 1 | |a Ayoub, A |e investigator |4 oth | |
| 700 | 1 | |a Babores, M |e investigator |4 oth | |
| 700 | 1 | |a Baggott, R |e investigator |4 oth | |
| 700 | 1 | |a Bagshaw, J |e investigator |4 oth | |
| 700 | 1 | |a Baguley, D |e investigator |4 oth | |
| 700 | 1 | |a Bailey, L |e investigator |4 oth | |
| 700 | 1 | |a Baillie, J K |e investigator |4 oth | |
| 700 | 1 | |a Bain, S |e investigator |4 oth | |
| 700 | 1 | |a Bakali, M |e investigator |4 oth | |
| 700 | 1 | |a Bakau, M |e investigator |4 oth | |
| 700 | 1 | |a Baldry, E |e investigator |4 oth | |
| 700 | 1 | |a Baldwin, D |e investigator |4 oth | |
| 700 | 1 | |a Baldwin, M |e investigator |4 oth | |
| 700 | 1 | |a Ballard, C |e investigator |4 oth | |
| 700 | 1 | |a Banerjee, A |e investigator |4 oth | |
| 700 | 1 | |a Bang, B |e investigator |4 oth | |
| 700 | 1 | |a Barker, R E |e investigator |4 oth | |
| 700 | 1 | |a Barman, L |e investigator |4 oth | |
| 700 | 1 | |a Barratt, S |e investigator |4 oth | |
| 700 | 1 | |a Barrett, F |e investigator |4 oth | |
| 700 | 1 | |a Basire, D |e investigator |4 oth | |
| 700 | 1 | |a Basu, N |e investigator |4 oth | |
| 700 | 1 | |a Bates, M |e investigator |4 oth | |
| 700 | 1 | |a Bates, A |e investigator |4 oth | |
| 700 | 1 | |a Batterham, R |e investigator |4 oth | |
| 700 | 1 | |a Baxendale, H |e investigator |4 oth | |
| 700 | 1 | |a Bayes, H |e investigator |4 oth | |
| 700 | 1 | |a Beadsworth, M |e investigator |4 oth | |
| 700 | 1 | |a Beckett, P |e investigator |4 oth | |
| 700 | 1 | |a Beggs, M |e investigator |4 oth | |
| 700 | 1 | |a Begum, M |e investigator |4 oth | |
| 700 | 1 | |a Beirne, P |e investigator |4 oth | |
| 700 | 1 | |a Bell, D |e investigator |4 oth | |
| 700 | 1 | |a Bell, R |e investigator |4 oth | |
| 700 | 1 | |a Bennett, K |e investigator |4 oth | |
| 700 | 1 | |a Beranova, E |e investigator |4 oth | |
| 700 | 1 | |a Bermperi, A |e investigator |4 oth | |
| 700 | 1 | |a Berridge, A |e investigator |4 oth | |
| 700 | 1 | |a Berry, C |e investigator |4 oth | |
| 700 | 1 | |a Betts, S |e investigator |4 oth | |
| 700 | 1 | |a Bevan, E |e investigator |4 oth | |
| 700 | 1 | |a Bhui, K |e investigator |4 oth | |
| 700 | 1 | |a Bingham, M |e investigator |4 oth | |
| 700 | 1 | |a Birchall, K |e investigator |4 oth | |
| 700 | 1 | |a Bishop, L |e investigator |4 oth | |
| 700 | 1 | |a Bisnauthsing, K |e investigator |4 oth | |
| 700 | 1 | |a Blaikely, J |e investigator |4 oth | |
| 700 | 1 | |a Bloss, A |e investigator |4 oth | |
| 700 | 1 | |a Bolger, A |e investigator |4 oth | |
| 700 | 1 | |a Bolton, C E |e investigator |4 oth | |
| 700 | 1 | |a Bonnington, J |e investigator |4 oth | |
| 700 | 1 | |a Botkai, A |e investigator |4 oth | |
| 700 | 1 | |a Bourne, C |e investigator |4 oth | |
| 700 | 1 | |a Bourne, M |e investigator |4 oth | |
| 700 | 1 | |a Bramham, K |e investigator |4 oth | |
| 700 | 1 | |a Brear, L |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Immunity & ageing : I & A |d 2004 |g 21(2024), 1 vom: 11. Jan., Seite 6 |w (DE-627)NLM153387815 |x 1742-4933 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:1 |g day:11 |g month:01 |g pages:6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12979-023-00406-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 1 |b 11 |c 01 |h 6 | ||